Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PLK1 | P53350 | 7/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.44 |
| ▸ | ABAT | P80404 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24212110 | 0.94 | HDAC6 (0.53) | HDAC2HDAC8HDAC6ALDH1A1HPGD | |
| SCHEMBL5391427 | 0.89 | HPGD (0.76) | HDAC2HDAC8HDAC6ALDH1A1HPGD | |
| SCHEMBL14358587 | 0.84 | HDAC6 (0.68) | HDAC2HDAC8HDAC6ALDH1A1HPGD | |
| SCHEMBL14358593 | 0.84 | HDAC6 (0.68) | HDAC2HDAC8HDAC6ALDH1A1HPGD | |
| SCHEMBL7538748 | 0.83 | ALDH1A1 (0.55) | HDAC2HDAC8HDAC6ALDH1A1HPGD | |
| SCHEMBL250247 | 0.83 | HDAC6 (0.80) | HDAC2HDAC8HDAC6ALDH1A1HPGD | |
| SCHEMBL31482044 | 0.81 | MRGPRX4 (0.56) | ALDH1A1HPGDTSHRHTTSMN1; SMN2 | |
| SCHEMBL6681528 | 0.81 | HDAC8 (0.57) | HDAC2HDAC8HDAC6ALDH1A1HPGD | |
| SCHEMBL15358837 | 0.80 | HDAC1 (0.64) | HDAC2HDAC8HDAC6ALDH1A1CA2 | |
| SCHEMBL20057794 | 0.79 | BAZ2B (0.68) | ALDH1A1SMN1; SMN2MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932639-B2 | Fused ring heteroaryl compounds as ALK4/5 inhibitors | BISICHEM CO., LTD. (KR) | 2024-03-19 | — | — | US | disclosed |
| EP-3892278-B1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023183628-A9 | TARGETED DELIVERY | JUDO BIO INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230303999-A1 | COMBINATORIAL PLATFORM FOR HIGH-THROUGHPUT POLYNUCLEOTIDE-ENCODED CATALYST DISCOVERY | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-09-28 | — | — | US | disclosed |
| WO-2023183628-A2 | TARGETED DELIVERY | JUDO BIO INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230273194-A1 | NON-INVASIVE METHOD FOR DETECTION OF ENZYME ACTIVITY IN VIVO, SUBSTRATES AND A DEVICE THEREFORE | ETH Zürich (CH) | 2023-08-31 | — | — | US | disclosed |
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| US-11702652-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| US-11560401-B2 | Method for preparing oligonucleic acid compound | NIPPON SHINYAKU CO., LTD. (JP) | 2023-01-24 | — | — | US | disclosed |
| US-20230014840-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | NIPPON SHINYAKU CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| EP-1351928-A2 | NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER S.A. (FR) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002053516-A2 | N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER SA (FR) | 2002-07-11 | — | — | WO | disclosed |
| EP-0622361-B1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-6169095-B1 | FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES IN THE EYE, SUCH AS ALLERGY, INFLAMMATION AND PAIN OF THE EYE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| US-5981533-A | INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR EPIDERMAL GROWTH FACTOR AND CAN BE USED IN THE CASE OF EPIDERMAL HYPERPROLIFERATION (PSORIASIS) AND AS ANTI-TUMOR AGENTS | NOVARTIS AG (CH) | 1999-11-09 | — | — | US | disclosed |
| US-5922711-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES, SHOCK OR ANALGESICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-07-13 | — | — | US | disclosed |
| CN-1043344-C | New heterocyclic compounds | KRONSEDER MASCHF KRONES (JP) | 1999-05-12 | — | — | CN | disclosed |
| US-5708173-A | PREPARATION OF SUBSTITUTED QUINOLINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| US-5563162-A | CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| EP-0622361-A1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932639-B2 | Fused ring heteroaryl compounds as ALK4/5 inhibitors | ALK, FGFR4, ALKBH3 | HDAC2 2463/4885HDAC8 1877/4885HDAC6 2078/4885 |
| US-11560401-B2 | Method for preparing oligonucleic acid compound | POLRMT, POLI, POLR2H | HDAC2 644/4885HDAC8 894/4885HDAC6 1190/4885 |
| US-20230014840-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | DNASE1, XRN2, FBL | HDAC2 742/4885HDAC8 2452/4885HDAC6 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.